Pancreatic Cancer Research

Clinical trialObservationalUnknown

Prognostic Biomarkers of Pancreatic Cancer Based on Proteomics Techniques

Outcome
Outcome unknown
Phase
Observational
Status
Unknown
Study type
Observational
Start
13 May 2021
Listed end
12 March 2022
Enrollment
20 participants
Sites
1
Primary outcomes
Differentially expressed proteins in tumor and paracancer tissues
Sponsor type
Academic / other
Results posted
No
Last update
21 October 2021

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

In this study, we will use high-throughput proteomics techniques to search for biomarkers of post-operative prognosis of pancreatic cancer in samples of patients who have been diagnosed with pancreatic cancer through bioinformatics analysis.

Detailed description public domain (ClinicalTrials.gov)

This study plan from the affiliated hospital of Qingdao university collected 20 cases of patients with pancreatic cancer pathological tissue samples and clinical data, including clinical diagnostic information, laboratory tests, imaging examination results and other information data), through high-throughput proteomic technology in pancreatic cancer pathological finding biomarkers, the bioinformatics analysis to explore the prognosis biomarkers.